Document is current
Any future updates will be listed below
-
Authors
Dwarkanath, Pratibha
Muhihi, Alfa
Sudfeld, Christopher R.
Rani, Shobha
Duggan, Christopher P.
Sando, Mary M.
Wylie, Blair J.
Fernandez, Ryan
Kinyogoli, Shabani
Munk, Cristina
Perumal, Nandita
Raj, John Michael
Buggi, Nirmala
Swai, Ndeniria
Thomas, Tinku
Wang, Molin
Kurpad, Anura V.
Masanja, Honorati
Pembe, Andreas B.
Fawzi, Wafaie W.
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1172660)
National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK104676)
Canadian Institutes of Health Research (None)
- License Information
-
More Information
Article History
Received: 14 April 2021
Accepted: 9 November 2021
First Online: 24 November 2021
Declarations
:
: The India trial protocol was approved by the Harvard T. H. Chan School of Public Health Institutional Review Board (Ref. No. IRB18-0157), the St. John’s Institutional Ethics Committee (IEC Study Ref. No. 197/2017), and the Indian Council of Medical Research (Ref. No. 2018-0380). The Tanzania trial protocol was approved by the Harvard T. H. Chan School of Public Health Institutional Review Board (Ref. No. IRB17-1874), the Ifakara Health Institute Institutional Review Board (IHI/IRB/No: 002-2018), the Muhimbili University of Health and Allied Sciences Institutional Review Board (MUHAS-REC-3-2020-107), the National Health Research Ethics Sub-Committee (NatHREC) (Ref. No. NIMR/HQ/R.8a/Vol. IX/2752), and the Tanzania Medicines and Medical Devices Authority (TMDA) (Ref No. TFDA0018/CTR/0010/01). All participants in the India and Tanzania trials will provide written informed consent for trial enrollment.
: Not applicable.
: No competing interests to report for any authors or trial staff member.
